Background Selective toxicity antibacteribiotics is considered to be due to interactions with
targets either being unique to bacteria or being characterized by a dichotomy between pro …

Conventional therapeutic approaches for cancer generally involve chemo-and radiation
therapies that often exhibit low efficacy and induce toxic side effects. Recent years have …

The earliest events during human tumour initiation, although poorly characterized, may hold
clues to malignancy detection and prevention. Here we model occult preneoplasia by …

Like any genome, mitochondrial DNA (mtDNA) also requires the action of topoisomerases to
resolve topological problems in its maintenance, but for a long time, little was known about …

Compounds routinely used to increase the quality of life and combat disease undergo
stringent potency and biosafety tests before approval. However, based on the outcome of …

Reviewed are the phosphorylation events reporting activation of protein kinases and the key
substrates critical for the DNA damage signaling (DDS). These DDS events are detected …

The earliest events during human tumor initiation, while poorly characterized, may hold
clues to malignancy detection and prevention. Here we model occult pre-neoplasia by bi …

Because of their essentiality for DNA replication, transcription, and repair, type II
topoisomerases are targets for antibacterial and anticancer drugs. There are two type II …

ABSTRACT Gepotidacin (GSK2140944), a novel triazaacenaphthylene bacterial
topoisomerase inhibitor, is currently in clinical development for the treatment of bacterial …

ABSTRACT GSK2140944 is a novel bacterial type II topoisomerase inhibitor with in vitro
activity against key causative respiratory pathogens, including methicillin-resistant …